These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 31834939)
1. Use of Direct Oral Anticoagulants in Morbidly Obese Patients. Kido K; Lee JC; Hellwig T; Gulseth MP Pharmacotherapy; 2020 Jan; 40(1):72-83. PubMed ID: 31834939 [TBL] [Abstract][Full Text] [Related]
2. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation. Kido K; Ngorsuraches S Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients. Kalani C; Awudi E; Alexander T; Udeani G; Surani S Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732 [No Abstract] [Full Text] [Related]
4. Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review. Zhao Y; Guo M; Li D; Xu W; Pan C; He C; Cui X Clin Appl Thromb Hemost; 2023; 29():10760296231153638. PubMed ID: 36760080 [TBL] [Abstract][Full Text] [Related]
5. A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. Patil T; Lebrecht M Thromb Res; 2020 Aug; 192():124-130. PubMed ID: 32473496 [TBL] [Abstract][Full Text] [Related]
6. Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-analysis. Mhanna M; Beran A; Al-Abdouh A; Sajdeya O; Abdulsattar W; Srour O; Ayesh H; Alom M; Khuder SA; Hamouda D; Assaly R Am J Ther; 2021 Jun; 28(5):e531-e539. PubMed ID: 34491953 [TBL] [Abstract][Full Text] [Related]
7. Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation. Kido K; Shimizu M; Shiga T; Hashiguchi M Am J Cardiol; 2020 Jul; 126():23-28. PubMed ID: 32345473 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis. Katel A; Aryal M; Neupane A; Gosain R; Pathak R; Bhandari Y; Kouides P Cureus; 2021 Apr; 13(4):e14572. PubMed ID: 34026385 [TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. Perales IJ; San Agustin K; DeAngelo J; Campbell AM Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028 [No Abstract] [Full Text] [Related]
10. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
12. A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease. Starr JA; Pinner NA; Mannis M; Stuart MK Ann Pharmacother; 2022 Jun; 56(6):691-703. PubMed ID: 34459281 [TBL] [Abstract][Full Text] [Related]
13. Direct Oral Anticoagulants in Obesity: An Updated Literature Review. Sebaaly J; Kelley D Ann Pharmacother; 2020 Nov; 54(11):1144-1158. PubMed ID: 32443941 [TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis. Elshafei MN; Mohamed MFH; El-Bardissy A; Ahmed MB; Abdallah I; Elewa H; Danjuma M J Thromb Thrombolysis; 2021 Feb; 51(2):388-396. PubMed ID: 32556939 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis. Thangjui S; Kewcharoen J; Yodsuwan R; Trongtorsak A; Thyagaturu H; Shrestha B; Winans ARM; Bischof E Eur Heart J Cardiovasc Pharmacother; 2022 Jun; 8(4):325-335. PubMed ID: 33730164 [TBL] [Abstract][Full Text] [Related]
16. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants. Cohen AT; Hill NR; Luo X; Masseria C; Abariga SA; Ashaye AO Int J Cardiol; 2018 Oct; 269():174-181. PubMed ID: 30037626 [TBL] [Abstract][Full Text] [Related]
17. Dilemmas Related to Direct-Acting Oral Anticoagulant Administration in Patients With Extreme Obesity. Erstad BL; Barletta JF Ann Pharmacother; 2023 Jun; 57(6):727-737. PubMed ID: 36258660 [TBL] [Abstract][Full Text] [Related]
18. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081 [TBL] [Abstract][Full Text] [Related]
19. Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review. Nasser MF; Jabri A; Gandhi S; Rader F Am J Med; 2021 Dec; 134(12):1465-1475. PubMed ID: 34403701 [TBL] [Abstract][Full Text] [Related]